2. IDEXX Laboratories ( IDXX) develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, water testing and dairy markets. Broadly, the company operates in two business segments: Companion Animal Group, and Livestock and Poultry Diagnostics. Besides, IDEXX sells products for the dairy and human point-of-care medical diagnostics market. The company will release its second quarter 2011 results on July 22.

Analysts polled by Bloomberg expect IDEXX to record second-quarter net income of $42.54 million or 72 cents per share, versus $37.19 million or 62 cents per share in the same quarter prior year. Sales are expected to rise by 10% to $309.33 million from $281.48 million earlier. Operating profit is seen increasing by 14% to $62.67 million, while EBITDA is pegged 11% higher at $73.75 million.

Recently, the company announced plans to build a $60 million corporate headquarters through restricting activities at a nearby quarry, allowing the company to accommodate almost 700 new workers. Initially, the project would start with the construction of a $30 million, 107,000-square-foot building that will include offices for 300 persons, a fitness center and a food service area.

Of the 12 analysts covering the stock, 33% recommend a buy and 58% suggest a hold. Analysts polled by Bloomberg foresee the stock gaining an average 2.4% to $81.50 in the upcoming 12 months.

If you liked this article you might like

Edwards Lifesciences: Cramer's Top Takeaways

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Hold on Concert's Hair Loss Trials Pushes Shares Down 10%

Edwards Lifesciences Is Not Skipping A Beat

Canaccord Says Edwards Lifesciences Is Its Favorite Med Tech Stock